The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin
Conditions
Gastrointestinal Hemorrhage
Conditions: official terms
Gastrointestinal Hemorrhage
Conditions: Keywords
Gastrointestinal bleeding, Lower gastrointestinal bleeding (LGIB), Polypectomy, Large colorectal polyps, ASA, Aspirin, Acetylsalicylic acid, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases
Study Type
Interventional
Study Phase
Phase 4
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Intervention
Name: Aspirin (ASA) Type: Drug
Name: Placebo Type: Drug
Overall Status
Not yet recruiting
Summary
The risk of bleeding after polypectomy of large colorectal polyps in patients taking aspirin is uncertain. This is a randomized, multi-center, placebo-controlled, double-blind study to compare the risk of significant bleeding after endoscopic polypectomy of large (>=10mm) colorectal polyps in patients continuing or discontinuing on daily acetylsalicylic acid (ASA) use. Eligible patients will be randomly assigned in a 1:1 ratio to a group taking 75mg daily ASA or placebo 7 days before and 14 days following polypectomy. The primary endpoint of the study is bleeding within 30 days from colorectal polypectomy. The secondary endpoints are composite cardiovascular events occurring between the date of randomization and 30 days after polypectomy.
Detailed Description
Patients chronically taking aspirin (in prophylaxis doses 75-325 mg), with a diagnosis of colorectal polyps ≥ 10 mm in diameter will be enrolled on a routine polypectomy under hospitalization. Meeting the inclusion criteria, after informed consent and a cardiologist consent the patient will receive aspirin/placebo, and The Patient Diary to fill (Visit 1). The patient will be admitted to the Study Center in 6-7 days taking on the aspirin/placebo and prepared for the study (Visit 2). Patient will be under the care of a physician after polypectomy by a minimum of 6 hours. 14 days after polypectomy will be the first control visit, during which the physician will take back patient diary and pack treatment (Visit 3). 30 days after polypectomy will be the second control visit by phone (Visit 4). Patients will be monitored by looking at the end points.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 40 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Age 40 years or older

2. Daily aspirin for primary or secondary prophylaxis

3. Candidate for endoscopic polypectomy of at least one colorectal polyp 10mm or larger

4. Signed written informed consent

5. Written opinion from a cardiologist that the patient can cease taking aspirin for a period of 21 days in the peri-polypectomy period

Exclusion Criteria:

1. Lifelong anticoagulant therapy with warfarin, acenocumarol

2. Concurrent antiplatelet treatment with clopidogrel or ticlopidin

3. Coagulation disorders INR > 1,5, APTT 2xnorm

4. Known hemorrhagic disorder
Location
Start Date
September 2012
Completion Date
September 2015
Sponsors
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Source
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page